IgG4 (MRQ-44) Mouse Monoclonal Antibody
Specialties: Gastrointestinal (GI) Pathology Anatomic Pathology
IgG4-related sclerosing disease has been recognized as a systemic disease entity characterized by elevated IgG4 levels and diffuse lymphoplasmacytic infiltration with the presence of many IgG4-positive plasma cells. Clinical manifestations are apparent in the pancreas, bile duct, gall bladder, lacrimal gland, salivary gland, retroperitoneum, kidney, lung, breast, thyroid, and prostate. Immunohistochemical analyses of IgG4-related sclerosing disease exhibit significantly more than normal IgG4-positive plasma cells in affected tissues. 1-8
- Sakata N, et al. IgG4-positive plasma cells in inflammatory abdominal aortic aneurysm: the possibility of an aortic manifestation of IgG4-related sclerosing disease. Am J Surg Pathol. 2008; 32:553-9.
- Dhobale S, et al. IgG4 related sclerosing disease with multiple organ involvements and response to corticosteroid treatment. J Clin Rheumatol. 2009; 15:354-7.
- Li Y, et al. Immunohistochemistry of IgG4 can help subclassify Hashimoto's autoimmune thyroiditis. Pathol Int. 2009; 59:636-41.
- Cheuk W, et al. IgG4-related sclerosing mastitis: description of a new member of the IgG4-related sclerosing diseases. Am J Surg Pathol. 2009; 33:1058-64.
- Deshpande V, et al. IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material. Mod Pathol. 2009; 22:1287-95.
- Sato Y, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease. Mod Pathol. 2009; 22: 589-99.
- Koyabu M, et al. Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. J Gastroenterol. 2010; 45:732-41.
- Kamisawa T, et al. Sclerosing cholangitis associated with autoimmune pancreatitis differs from primary sclerosing cholangitis. World J Gastroenterol. 2009; 21:2357-60.
Specifications
- Reactivity: paraffin
- Control: Tonsil (Cytoplasmic)
- Dilution Range: 1:100-1:500 *
Package Inserts
IFU
- IVD Rev. 4.0 (CMC36721040)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 367M-14 |
| 0.5 mL concentrate | 367M-15 |
| 1.0 mL concentrate | 367M-16 |
| 1.0 mL predilute ready-to-use | 367M-17 |
| 7.0 mL predilute ready-to-use | 367M-18 |
For in vitro diagnostic (IVD) use in Canada
| 0.1 mL concentrate | 367M-14 |
| 0.5 mL concentrate | 367M-15 |
| 1.0 mL concentrate | 367M-16 |
| 1.0 mL predilute ready-to-use | 367M-17 |
| 7.0 mL predilute ready-to-use | 367M-18 |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 367M-14 |
| 0.5 mL concentrate | 367M-15 |
| 1.0 mL concentrate | 367M-16 |
| 1.0 mL predilute ready-to-use | 367M-17 |
| 7.0 mL predilute ready-to-use | 367M-18 |
For research use only (RUO) in Japan
| 0.1 mL concentrate (RUO) | 367M-14-RUO |
| 0.5 mL concentrate (RUO) | 367M-15-RUO |
| 1.0 mL concentrate (RUO) | 367M-16-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 367M-17-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 367M-18-RUO |
To request information on this product in additional countries, please click the button below.